FR2366019A1 - Solution injectable de l-pyroglutamyl-l-histidyl -l-prolinamide - Google Patents

Solution injectable de l-pyroglutamyl-l-histidyl -l-prolinamide

Info

Publication number
FR2366019A1
FR2366019A1 FR7729569A FR7729569A FR2366019A1 FR 2366019 A1 FR2366019 A1 FR 2366019A1 FR 7729569 A FR7729569 A FR 7729569A FR 7729569 A FR7729569 A FR 7729569A FR 2366019 A1 FR2366019 A1 FR 2366019A1
Authority
FR
France
Prior art keywords
pyroglutamyl
prolinamide
histidyl
injectable solution
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7729569A
Other languages
English (en)
French (fr)
Other versions
FR2366019B1 (OSRAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of FR2366019A1 publication Critical patent/FR2366019A1/fr
Application granted granted Critical
Publication of FR2366019B1 publication Critical patent/FR2366019B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/066—TRH, thyroliberin, thyrotropin releasing hormone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR7729569A 1976-10-01 1977-09-30 Solution injectable de l-pyroglutamyl-l-histidyl -l-prolinamide Granted FR2366019A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP51118875A JPS5920647B2 (ja) 1976-10-01 1976-10-01 注射剤

Publications (2)

Publication Number Publication Date
FR2366019A1 true FR2366019A1 (fr) 1978-04-28
FR2366019B1 FR2366019B1 (OSRAM) 1981-02-06

Family

ID=14747271

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7729569A Granted FR2366019A1 (fr) 1976-10-01 1977-09-30 Solution injectable de l-pyroglutamyl-l-histidyl -l-prolinamide

Country Status (11)

Country Link
US (1) US4167563A (OSRAM)
JP (1) JPS5920647B2 (OSRAM)
AU (1) AU509037B2 (OSRAM)
BE (1) BE859277A (OSRAM)
CA (1) CA1092024A (OSRAM)
DE (1) DE2743586C2 (OSRAM)
FR (1) FR2366019A1 (OSRAM)
GB (1) GB1592336A (OSRAM)
HK (1) HK27884A (OSRAM)
MY (1) MY8500267A (OSRAM)
NL (1) NL188928C (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251657A3 (en) * 1986-06-26 1988-06-22 Cetus-Ben Venue Therapeutics Therapeutic compositions with galactitol as carrier

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58167516A (ja) * 1982-03-29 1983-10-03 Daigo Eiyou Kagaku Kk 糖、アミノ酸、電解質輸液の製造法
US4493828A (en) * 1982-07-26 1985-01-15 Merck & Co., Inc. Use of thyrotropin releasing hormone and related peptides as poultry growth promotants
JPS60190711A (ja) * 1984-03-09 1985-09-28 Tokyo Tanabe Co Ltd プロトポルフイリン類注射用製剤
US4608365A (en) * 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
NL8701143A (nl) * 1986-05-27 1987-12-16 Sandoz Ag Farmaceutische preparaten.
CA2199734A1 (en) * 1994-09-12 1996-03-21 Fraser Aird Corticotropin release inhibiting factor and methods of using same
US6039956A (en) * 1994-09-12 2000-03-21 Pennsylvania, Trustees Of The University Of, The Corticotropin release inhibiting factor and methods of using same for treating behavioral symptoms in an anxiety disorder
EP1336410A4 (en) * 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266415C (OSRAM) *
US3322629A (en) * 1963-06-14 1967-05-30 Evans Medical Ltd Injectable aqueous solutions containing a protamine-active compound
NL6811058A (OSRAM) * 1967-08-02 1969-02-04 Diagnostic Data Inc
FR2221128A2 (en) * 1973-03-13 1974-10-11 Fabre Sa Pierre Aspirin - polyol compsns. - contg. inositol, ribitol or glucuronic acid - free from ulcerogenic activity
FR2221127A2 (en) * 1973-03-13 1974-10-11 Fabre Sa Pierre Corticoid or pyrazolone compsns. - contg. a natural polyol-free from Cerogenic activity
US3865934A (en) * 1973-04-02 1975-02-11 Abbott Lab Method of enhancing memory and learning
US3873709A (en) * 1974-02-19 1975-03-25 Abbott Lab Method of treating psychosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5121050B1 (OSRAM) 1962-04-07 1976-06-30
DE2410821A1 (de) * 1974-03-07 1975-09-18 Hoechst Ag Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung
US3959248A (en) * 1974-04-03 1976-05-25 Merck & Co., Inc. Analogs of thyrotropin-releasing hormone
GB1523598A (en) * 1975-03-08 1978-09-06 Reckitt & Colmann Prod Ltd Tripeptides
JPS51118841A (en) * 1975-04-03 1976-10-19 Takeda Chem Ind Ltd A drug for improving and treating clouding of consciousness

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266415C (OSRAM) *
US3322629A (en) * 1963-06-14 1967-05-30 Evans Medical Ltd Injectable aqueous solutions containing a protamine-active compound
NL6811058A (OSRAM) * 1967-08-02 1969-02-04 Diagnostic Data Inc
FR2221128A2 (en) * 1973-03-13 1974-10-11 Fabre Sa Pierre Aspirin - polyol compsns. - contg. inositol, ribitol or glucuronic acid - free from ulcerogenic activity
FR2221127A2 (en) * 1973-03-13 1974-10-11 Fabre Sa Pierre Corticoid or pyrazolone compsns. - contg. a natural polyol-free from Cerogenic activity
US3865934A (en) * 1973-04-02 1975-02-11 Abbott Lab Method of enhancing memory and learning
US3873709A (en) * 1974-02-19 1975-03-25 Abbott Lab Method of treating psychosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251657A3 (en) * 1986-06-26 1988-06-22 Cetus-Ben Venue Therapeutics Therapeutic compositions with galactitol as carrier

Also Published As

Publication number Publication date
JPS5344616A (en) 1978-04-21
NL188928B (nl) 1992-06-16
AU2907177A (en) 1979-03-29
GB1592336A (en) 1981-07-08
NL7710693A (nl) 1978-04-04
US4167563A (en) 1979-09-11
AU509037B2 (en) 1980-04-17
JPS5920647B2 (ja) 1984-05-15
BE859277A (fr) 1978-03-30
DE2743586C2 (de) 1987-01-29
HK27884A (en) 1984-03-30
CA1092024A (en) 1980-12-23
FR2366019B1 (OSRAM) 1981-02-06
NL188928C (nl) 1992-11-16
MY8500267A (en) 1985-12-31
DE2743586A1 (de) 1978-04-06

Similar Documents

Publication Publication Date Title
IT8447603A0 (it) Reattivo liquido pronto per l'uso per la determinazione del contenuto di glucosio nel sangue
ES279722Y (es) Filtro para liquido apropiado para ser utilizado en un circuito extracorporeo de circulacion de sangre.
BE810967A (fr) Traitement de l'eau
FR2451392A1 (OSRAM)
FR2366019A1 (fr) Solution injectable de l-pyroglutamyl-l-histidyl -l-prolinamide
FR2450605A1 (fr) Composition pour traiter la cavite orale et procede de preparation
FR2509613B1 (fr) Medicament a base d'insuline pour le traitement du diabete sucre
BE869152A (fr) Dispositif pour le traitement de la surface de corps presentant des contours irreguliers
FR2489137B1 (fr) Dispositif destine a produire des faisceaux lumineux, notamment pour l'orientation d'un objet tel que le corps d'un patient soumis a une tomographie
SU513645A3 (ru) Реактив дл определени глюкозы
IT953539B (it) Fotometro per determinare il con tenuto di ossigeno nel sangue
FR2290510A1 (fr) Solution d'activation electrolytique pour le traitement du zirconium et de ses alliages
ES460743A1 (es) Procedimiento para la obtencion de preparados medicinales con ph acido.
FR2319382A1 (fr) Seringue d'injection pour l'injection de liquide dans des vaisseaux sanguins
FR2347080A1 (fr) Filtre pour canalisations de liquides, notamment d'eau de consommation
FR2311303A1 (fr) Agent de diagnostic pour detecter l'urobilinogene
JPS53136126A (en) Liquid fuel injection pump
FR2383665A1 (fr) Nouvelle composition therapeutique a base de trans broparestrol
BE871753A (fr) Nouvelle utilisation therapeutique de l'acetyl-1-carnitine pour le traitement des affections cardiaques
BE860607A (fr) Composition pour le dosage enzymatique du glucose
IT1215408B (it) Dispositivo per l'adduzione dosata di lega leggera liquida nel cilindro di pressione.
FR1197808A (fr) Instrument pour l'extraction de corps étrangers situés dans des canaux physiologiques
CH518057A (fr) Nouvelle composition liquide stable dispersible dans l'eau et son procédé de préparation
FR2390166A1 (fr) Composition medicamenteuse a base de benzothiazole-2-sulfamide et de sulfate de baryum
JPS5267296A (en) Liquid crystal display element